BACKGROUND: Inflammatory mechanisms may play an important role in the pathogenesis of cisplatin nephrotoxicity. Agonists of the peroxisome proliferator-activated receptor-gamma (PPARgamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules. The purpose of this study was to examine the protective effects of rosiglitazone on cisplatin nephrotoxicity and to explore the mechanism of its renoprotection. METHODS: Mice were treated with cisplatin with or without pre-treatment with rosiglitazone. Renal functions, histological findings, aquaporin 2 (AQP2) and adhesion molecule expression, macrophage infiltration and tumour necrosis factor-alpha (TNF-alpha) levels were investigated. The effect of rosiglitazone on nuclear factor (NF)-kappaB activity and on viability was examined using cultured human kidney (HK-2) cells. RESULTS: Rosiglitazone significantly decreased both the damage to renal function and histological pathology after cisplatin injection. Pre-treatment with rosiglitazone reduced the systemic levels of TNF-alpha and down-regulated adhesion molecule expression in addition to the infiltration of inflammatory cells after cisplatin administration. Rosiglitazone restored the decreased AQP2 expression after cisplatin treatment. Pre-treatment with rosiglitazone blocked the phosphorylation of the p65 subunit of NF-kappaB in cultured HK-2 cells. Rosiglitazone had a protective effect via a PPARgamma-dependent pathway in cisplatin-treated HK-2 cells. CONCLUSION: These results showed that pre-treatment with rosiglitazone attenuates cisplatin-induced renal damage through the suppression of TNF-alpha overproduction and NF-kappaB activation.
BACKGROUND: Inflammatory mechanisms may play an important role in the pathogenesis of cisplatinnephrotoxicity. Agonists of the peroxisome proliferator-activated receptor-gamma (PPARgamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules. The purpose of this study was to examine the protective effects of rosiglitazone on cisplatinnephrotoxicity and to explore the mechanism of its renoprotection. METHODS:Mice were treated with cisplatin with or without pre-treatment with rosiglitazone. Renal functions, histological findings, aquaporin 2 (AQP2) and adhesion molecule expression, macrophage infiltration and tumour necrosis factor-alpha (TNF-alpha) levels were investigated. The effect of rosiglitazone on nuclear factor (NF)-kappaB activity and on viability was examined using cultured human kidney (HK-2) cells. RESULTS:Rosiglitazone significantly decreased both the damage to renal function and histological pathology after cisplatin injection. Pre-treatment with rosiglitazone reduced the systemic levels of TNF-alpha and down-regulated adhesion molecule expression in addition to the infiltration of inflammatory cells after cisplatin administration. Rosiglitazone restored the decreased AQP2 expression after cisplatin treatment. Pre-treatment with rosiglitazone blocked the phosphorylation of the p65 subunit of NF-kappaB in cultured HK-2 cells. Rosiglitazone had a protective effect via a PPARgamma-dependent pathway in cisplatin-treated HK-2 cells. CONCLUSION: These results showed that pre-treatment with rosiglitazone attenuates cisplatin-induced renal damage through the suppression of TNF-alpha overproduction and NF-kappaB activation.
Authors: Siva Kumar Solleti; Dawn M Simon; Sorachai Srisuma; Meltem C Arikan; Soumyaroop Bhattacharya; Tirumalai Rangasamy; Kaiser M Bijli; Arshad Rahman; Joseph T Crossno; Steven D Shapiro; Thomas J Mariani Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-05-29 Impact factor: 5.464
Authors: Md Abdul Hye Khan; Lauren Kolb; Melissa Skibba; Markus Hartmann; René Blöcher; Ewgenij Proschak; John D Imig Journal: Diabetologia Date: 2018-07-21 Impact factor: 10.122
Authors: Alan R Parrish; Gang Chen; Robert C Burghardt; Takaho Watanabe; Christophe Morisseau; Bruce D Hammock Journal: Cell Biol Toxicol Date: 2008-04-03 Impact factor: 6.691
Authors: Myung-Gyu Kim; Ha Na Yang; Hye-Won Kim; Sang-Kyung Jo; Won Yong Cho; Hyoung-Kyu Kim Journal: J Korean Med Sci Date: 2010-03-19 Impact factor: 2.153
Authors: Geoffrey D Girnun; Elnaz Naseri; Scott B Vafai; Lishu Qu; Jeffrey D Szwaya; Roderick Bronson; John A Alberta; Bruce M Spiegelman Journal: Cancer Cell Date: 2007-05 Impact factor: 31.743